- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01138787
Cholesterol Absorption Inhibition Study (CASTELL)
CASTELL = Cholesterol Absorption Study STErols (LL)
Rationale: Consuming Plant Sterols (PS) fortified foods is widely accepted as easy to apply, life-style change to combat modestly elevated plasma cholesterol concentrations. PS are typically formulated as PS fatty acid ester (PSE) from margarines. In this study, PS will be formulated in a new innovative type spread. To confirm that the new spread results in a comparable cholesterol absorption inhibition as the reference product a dual isotope cholesterol study is planned, prior to any larger efficacy study.
Primary objective: Cholesterol absorption inhibition (%) calculated from plasma concentration vs. time curves from labeled cholesterol, for the PS or PSE containing products, compared to a control product without PS or PSE.
Secondary objectives: PK parameters for cholesterol as derived from the plasma concentration vs. time curves.
Study design: Acute, single dose, double-blind, randomized, cross-over. Study population: 18 healthy, non-obese men (BMI 20-27 kg∙m-2, age range 20 - 65 yr) Test products: PS (2250 mg) formulated in innovatively processed spread (30 g); PSE (2250 mg PS) reference product (30 g); Control product without PS or PSE (30 g) Intervention: Three study periods during which a single dose of either Test, Reference or Control (regular light spread) spreads will be consumed together with standard breakfast. At each study period, 50 mg of D7-cholesterol is added to the meal and 30 mg of 13C-cholesterol is injected to measure cholesterol absorption. Before and four times after consumption of each spread, blood samples will be taken at 24 h intervals up to 7 days.
Key parameters: Enrichments of labeled cholesterol isotopes as determined by GCMS and IRMS. Fractional absorption is determined by the ratio of the two isotopes in plasma cholesterol after 7 days.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Verwacht)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Nederland
- Academisch Medisch Centrum, vasculaire geneeskunde
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Apparently healthy: no medical conditions which might effect study measurements (judged by study physician).
- Males aged 20 - 65
- BMI 20-27 kg∙m-2
- LDL-C levels between 3.0 - 5.0 mmol/L, triglycerides < 3.0 mmol/L
- Not more than 10 hours per week of strenuous exercise
- Ability to give informed consent.
- Ability to follow verbal and written instructions.
- Non-smoker (tobacco, marijuana).
- The ability to attend and to commute to the performance site for each of study day visit and follow-up throughout the study period are required.
- Willing to consume a breakfast in the morning of each study day.
- Willing to consume margarine on each study occasion.
- Having a general practitioner.
- No use of medication which interferes with study measurements (as judged by the study physician).
- Agreeing to be informed about medically relevant personal test-results after the screening visit by a physician.
- Consumption =< 21 alcoholic drinks in a typical week.
- No blood donation 1 month prior to pre-study examination or during the study.
- Has accessible veins on the forearm as determined by examination at screening.
- Not being an employee of Unilever.
- No reported participation in another nutritional or biomedical trial 3 months before the pre-study examination or during the study.
No reported participation in night shift work during the study.
Exclusion Criteria:
- Unwilling to refrain from consumption of plant sterol or stanol containing products one week before and during the study..
- Plasma lipid profile which indicates deviating lipid / cholesterol homeostasis, to be judged by study physician.
- Evidence of severe cardiovascular, respiratory, urogenital, gastrointestinal/ hepatic, hemato¬logical/ immunologic, HEENT (head, ears, eyes, nose, throat), dermatological/ connective tissue, musculoskeletal, metabolic/nutritional, endocrine, neurological/ psychiatric diseases, allergy, major surgery and/or laboratory assessments which might limit participation in or completion of the study protocol.
- Gastrointestinal or hepatic disorders influencing gastrointestinal absorption or transit, including gallstones or biliary diseases.
- History of surgery related to the gastro-intestinal tract
- On a medically prescribed or weight reduction diet
- Recreational (intravenous) drug use.
- The use of psychotropic drugs, including: benzodiazepines or alcohol in excess of 21 units/ week for males
- Concomitant medication that may modulate gastro-intestinal secretions and pH (e.g. antacids, proton-pump-inhibitors, prostaglandins, anticholinergic agents, H2-receptor antagonists)
- Concomitant medication that can alter gastric emptying (e.g. metoclopramide, cisapride, domperidone and erythromycin, anticholinergics, tricyclic antidepressants, narcotic analgesics, adrenergic agents, calcium channel blockers)
- Concomitant medication that can alter intestinal transit (e.g. loperamide, chemical/ osmotic/bulk laxatives), or influence satiety/energy intake (e.g. sibutramine, gluco¬corticoids, anabolic steroids)
- Intolerance or allergy for test product.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Preventie
- Toewijzing: Gerandomiseerd
- Interventioneel model: Crossover-opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: Reference spread
2250 mg PS (as PSE) in spread (30 g)
|
Single dose (30 gr) of spread, containing 2250 mg PS
|
Placebo-vergelijker: Placebo spread
regular light margarine (30 g)
|
Single dose (30 gr) of regular light margarine
|
Experimenteel: Test spread
2250 mg PS in innovatively processed spread (30 g)
|
Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
cholesterol absorption calculated from plasma cholesterol enrichments vs. time curves
Tijdsspanne: 5 blood samples within one week for each intervention
|
5 blood samples within one week for each intervention
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
---|---|
PK parameters derived from plasma curves (Cmax, Tmax, cholesterol pool, flux).
Tijdsspanne: 5 blood samples within one week for each intervention
|
5 blood samples within one week for each intervention
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Maud N Vissers, Dr. Ir, Academisch Medisch Centrum, afdeling vasculaire geneeskunde
- Studie directeur: Guus SM Duchateau, Dr, Unilever Research & Development Vlaardingen
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 09030V
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Cholesterol Absorption Inhibition
-
Texas A&M UniversityVoltooidCholesterol, LDL | Cholesterol, HDL | Onderzoek onderwerpenVerenigde Staten
-
Universidad Católica San Antonio de MurciaVoltooid
-
Universidad de GranadaUniversity of Copenhagen; University of Oxford; Harvard University; University Hospital... en andere medewerkersWerving
-
Uppsala UniversityDalarna County Council, SwedenVoltooid
-
University of California, Los AngelesIngetrokkenCholesterol VerlagingVerenigde Staten
-
Supplement Formulators, Inc.VoltooidCholesterol GezondheidVerenigde Staten
-
Yonsei UniversityVoltooid
-
Unity Health TorontoOnbekendLDL cholesterolCanada
-
University of Texas Southwestern Medical CenterMerck Sharp & Dohme LLC; Donald W. Reynolds FoundationVoltooidCholesterol, LDLVerenigde Staten
Klinische onderzoeken op Reference spread
-
Rabin Medical CenterOmega 3 GalileeWerving
-
TNOMinistry of Health, Welfare and SportVoltooid
-
Tampere UniversityKamuzu University of Health Sciences; Academy of Finland; Foundation for Paediatric... en andere medewerkersVoltooidOndervoeding | Ontwikkelingsachterstand | DwerggroeiMalawi
-
Tampere UniversityVoltooid
-
King's College LondonZoe Global LimitedWervingPostprandiale periode | Darm microbioom | Probiotisch | PrebiotischVerenigd Koninkrijk
-
Tampere UniversityAcademy of Finland; Foundation for Paediatric Research, FinlandVoltooid
-
Tampere UniversityKamuzu University of Health SciencesVoltooid
-
Washington University School of MedicineVoltooid
-
CochlearAvania; Trium Clinical ConsultingVoltooid